NASDAQ: PRCTProcept Biorobotics Corp Stock
$76.02-2.82 (-3.58%)
Updated Jan 17, 2025
PRCT Price
$76.02
Fair Value Price
N/A
Market Cap
$3.97B
52 Week Low
$44.52
52 Week High
$103.81
P/E
-38.98x
P/B
16.45x
P/S
20.85x
PEG
N/A
Dividend Yield
N/A
Revenue
$199.84M
Earnings
-$100.06M
Gross Margin
57.4%
Operating Margin
-47.9%
Profit Margin
-50.1%
Debt to Equity
0.55
Operating Cash Flow
-$92M
Beta
1.36
Next Earnings
Feb 25, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PRCT Overview
PROCEPT BioRobotics Corporations is a surgical robotics company advancing solutions in urology. The company offers the AquaBeam Robotic System, an image-guided, surgical robotic system used in minimally invasive urologic surgery, with an initial focus on benign prostatic hyperplasia. It has an install base of 130 AquaBeam Robotic Systems worldwide, 78 of which are in the U.S. PROCEPT BioRobotics was incorporated in 2007 and is headquartered in Redwood City, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PRCT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
C
Momentum
C
Sentiment
D
Safety
D
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important PRCT news, forecast changes, insider trades & much more!
PRCT News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRCT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRCT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRCT is poor value based on its book value relative to its share price (16.45x), compared to the US Medical Devices industry average (4.13x)
P/B vs Industry Valuation
PRCT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PRCT due diligence checks available for Premium users.
Valuation
PRCT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-38.98x
Industry
38.79x
Market
30.45x
PRCT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
16.45x
Industry
4.13x
PRCT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRCT's financial health
Profit margin
Revenue
$58.4M
Net Income
-$21.0M
Profit Margin
-35.9%
PRCT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PRCT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$374.1M
Liabilities
$132.9M
Debt to equity
0.55
PRCT's short-term assets ($322.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRCT's short-term assets ($322.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRCT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.8M
Investing
-$246.0k
Financing
$1.7M
PRCT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PRCT vs Medical Device Stocks
Procept Biorobotics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.